MCID: END035
MIFTS: 44

Endocrine Gland Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Endocrine Gland Cancer

MalaCards integrated aliases for Endocrine Gland Cancer:

Name: Endocrine Gland Cancer 12 15
Endocrine Neoplasm 12 54 17
Malignant Neoplasm of Endocrine Gland 12 71
Endocrine Gland Neoplasms 43 71
Malignant Tumour of Endocrine Gland 12
Neoplasm of the Endocrine System 29
Neoplasm of Endocrine System 12
Carcinoma of Endocrine Gland 71
Neoplasm of Endocrine Gland 12
Malignant Endocrine Tumor 12
Endocrine Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:170
ICD9CM 34 194.9
MeSH 43 D004701
NCIt 49 C3010 C3575
SNOMED-CT 67 93780007
ICD10 32 C75.9
UMLS 71 C0014132 C0153658 C1704374

Summaries for Endocrine Gland Cancer

Disease Ontology : 12 An organ system cancer located in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system.

MalaCards based summary : Endocrine Gland Cancer, also known as endocrine neoplasm, is related to non-functioning pancreatic endocrine tumor and carney complex variant. An important gene associated with Endocrine Gland Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include endocrine system, thyroid and pancreas.

Related Diseases for Endocrine Gland Cancer

Diseases related to Endocrine Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 non-functioning pancreatic endocrine tumor 35.1 SST GAST CHGA
2 carney complex variant 33.9 SST RET GNAS
3 islet cell tumor 33.8 SYP SST RET GAST CHGA
4 vipoma 33.6 SST GAST CHGA
5 thyroid gland cancer 33.4 SST RET MIR9-1 MIR483 MIR30A MIR221
6 neuroendocrine tumor 33.3 SYP SST RET GAST CHGA
7 pancreatic cancer 33.3 SST RET MIR483 MIR34A MIR30A MIR221
8 adrenal carcinoma 33.3 SYP SST MIR483 CHGA
9 carcinoid tumors, intestinal 31.9 SYP SST GAST CHGA
10 adenoma 31.8 SST RET GNAS CHGA
11 multiple endocrine neoplasia, type i 31.8 SYP SST RET MIR483 H2AC18 GNAS
12 thyroid gland medullary carcinoma 31.8 SYP SST RET GAST CHGA
13 thyroid carcinoma, familial medullary 31.7 SST RET GAST CHGA
14 gastrinoma 31.6 SST GAST CHGA
15 zollinger-ellison syndrome 31.6 SST GAST CHGA
16 neuroendocrine carcinoma 31.5 SYP SST GAST CHGA
17 primary hyperparathyroidism 31.5 RET GNAS GAST CHGA
18 small cell carcinoma 31.5 SYP GAST CHGA
19 pancreatic endocrine carcinoma 31.5 SYP SST GAST CHGA
20 glucagonoma 31.4 SST GAST CHGA
21 pineocytoma 31.4 SYP CHGA
22 neuroblastoma 31.4 SYP SST RET MIR34A MIR221 MIR21
23 ovarian serous cystadenocarcinoma 31.4 SYP MIR483 MIR30A MIR214 MIR196A1 MIR17
24 renal cell carcinoma, nonpapillary 31.4 RET MIR9-1 MIR34A MIR30A MIR221 MIR21
25 carcinoid syndrome 31.3 SYP SST CHGA
26 gastritis 31.3 SST GAST CHGA CCR6
27 parathyroid adenoma 31.3 RET GNAS CHGA
28 pituitary adenoma, prolactin-secreting 31.3 SST GNAS CHGA
29 cystadenoma 31.2 SYP GNAS CHGA
30 pancreatic adenocarcinoma 31.2 SST MIR221 MIR21 MIR196A1 GNAS GAST
31 malignant pheochromocytoma 31.2 SYP SST MIR483 CHGA
32 adrenocortical carcinoma, hereditary 31.2 MIR483 MIR214 GNAS
33 papillary carcinoma 31.2 SYP RET GNAS CHGA
34 somatostatinoma 31.2 SST GAST CHGA
35 pancreatoblastoma 31.2 SYP SST CHGA
36 serotonin syndrome 31.2 SST GAST CHGA
37 pancreatic ductal adenocarcinoma 31.2 MIR483 MIR221 MIR21 MIR199A1 MIR196A1
38 atrophic gastritis 31.2 SST GAST CHGA
39 acinar cell carcinoma 31.2 SYP GAST CHGA
40 constipation 31.2 SST RET GAST CHGA
41 adrenal cortical carcinoma 31.1 SYP MIR483 CHGA
42 small cell cancer of the lung 31.1 SYP SST MIR21 GAST CHGA
43 ampulla of vater neoplasm 31.1 SYP SST CHGA
44 peptic ulcer disease 31.1 SST H2AC18 GAST
45 in situ carcinoma 31.1 MIR30A MIR17 H2AC18
46 pancreatic gastrinoma 31.0 SYP SST GAST CHGA
47 thyroid gland papillary carcinoma 31.0 RET MIR9-1 MIR30A MIR221 MIR199A1 MIR17
48 leukemia, acute myeloid 31.0 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR21
49 duodenal gastrinoma 31.0 SST GAST CHGA
50 pancreatic cholera 31.0 SST GAST CHGA

Graphical network of the top 20 diseases related to Endocrine Gland Cancer:



Diseases related to Endocrine Gland Cancer

Symptoms & Phenotypes for Endocrine Gland Cancer

Drugs & Therapeutics for Endocrine Gland Cancer

Drugs for Endocrine Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3 Proton Pump Inhibitors Phase 4
4 Anti-Ulcer Agents Phase 4
5 Antacids Phase 4
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
Pancrelipase Approved, Investigational Phase 3 53608-75-6
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9 Hematinics Phase 2, Phase 3
10 Antimitotic Agents Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 pancreatin Phase 3
13 Immunologic Factors Phase 3
14 Gastrointestinal Agents Phase 3
15 Anti-Infective Agents Phase 3
16 Immunosuppressive Agents Phase 3
17 Antiviral Agents Phase 3
18 Antibodies, Monoclonal Phase 3
19 Antibodies Phase 3
20 Immunoglobulins Phase 3
21
Denosumab Approved Phase 2 615258-40-7
22
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8
24
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
25
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
26
Midazolam Approved, Illicit Phase 1, Phase 2 59467-70-8 4192
27 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
28
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
29
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
30
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
31
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
32
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
33
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
34
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
35
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
36
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
37
Fluorouracil Approved Phase 2 51-21-8 3385
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
40
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
41
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
42
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
43
Ondansetron Approved Phase 2 99614-02-5 4595
44
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
45
Levodopa Approved Phase 2 59-92-7 6047
46
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
47
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
48
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
49
Threonine Approved, Nutraceutical Phase 1, Phase 2 72-19-5 6288
50
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
2 Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
3 Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
4 Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
5 Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
6 Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases Recruiting NCT03590119 Phase 2, Phase 3 Lutetium Lu 177-DOTATATE
7 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
8 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel 125 mg/m2;gemcitabine 1000 mg/m2;gemcitabine 1000 mg/m2
9 Correlation Between SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors Enrolling by invitation NCT02840149 Phase 3 68Ga-DOTATATE PET/CT
10 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas Terminated NCT01231347 Phase 3 AMG 479;Placebo;AMG 479;gemcitabine
11 Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
12 A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors Completed NCT00688623 Phase 2 Everolimus
13 A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates Completed NCT00896454 Phase 2 denosumab
14 An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract Completed NCT00448136 Phase 2 bevacizumab [Avastin];5 FU;Streptozotocin;Xeloda
15 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
16 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
17 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
18 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
19 Evaluation of the Effect of Pasireotide LAR Administration in the Lymphocele Prevention After Axillary Node Dissection for Breast Cancer Completed NCT01356862 Phase 2 PASIREOTIDE;PLACEBO
20 A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer Recruiting NCT03535727 Phase 1, Phase 2 Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan;Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan
21 A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors Recruiting NCT03950609 Phase 2 Everolimus;Lenvatinib
22 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
23 Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II Recruiting NCT03717298 Phase 2
24 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
25 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
26 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
27 A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
28 Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors Active, not recruiting NCT01678664 Phase 2 Everolimus;Doxorubicin
29 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib;Sorafenib Tosylate
30 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Active, not recruiting NCT00514046 Phase 1, Phase 2 Vandetanib
31 Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan Terminated NCT00180960 Phase 2 Oxaliplatin and irinotecan
32 A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Terminated NCT00947167 Phase 2 pertuzumab;erlotinib
33 A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Terminated NCT01215578 Phase 2 Sutent
34 Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer Terminated NCT01555489 Phase 2 Ascorbic Acid
35 Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors Terminated NCT00609765 Phase 2 Avastin;Fluorouracil;Doxorubicin;Streptozocin;Dexamethasone;Ondansetron
36 Drug- Drug Interaction Study of JI-101 & Everolimus in Advanced Solid Tumors, Expansion Pharmacodynamic Study of JI-101 in Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers Terminated NCT01149434 Phase 1, Phase 2 JI-101;Everolimus
37 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
38 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
39 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
40 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
41 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
42 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Active, not recruiting NCT02909452 Phase 1 Entinostat;Pembrolizumab
43 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
44 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
45 Prospective Validation and Comparison of Subjective Assessment, the International Ovarian Tumor Analysis (IOTA) ADNEX Model, Logistic Regression Model LR2, Simple Rules and the Risk of Malignancy Index (RMI) for Discrimination Between Benign and Malignant Adnexal Masses in the Hands of Ultrasound Examiners With Different Levels of Experience Unknown status NCT02847832
46 Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging Unknown status NCT02836275
47 Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET Unknown status NCT01641679
48 A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours. Completed NCT02400996
49 Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer Completed NCT01341886 Metformin
50 Development of an Innovative Gallium 68 Radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation Completed NCT02134639

Search NIH Clinical Center for Endocrine Gland Cancer

Cochrane evidence based reviews: endocrine gland neoplasms

Genetic Tests for Endocrine Gland Cancer

Genetic tests related to Endocrine Gland Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Endocrine System 29

Anatomical Context for Endocrine Gland Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endocrine Gland Cancer:

19
Endocrine System

MalaCards organs/tissues related to Endocrine Gland Cancer:

40
Thyroid, Pancreas, Pituitary, Lung, Bone, Liver, Breast

Publications for Endocrine Gland Cancer

Articles related to Endocrine Gland Cancer:

(show top 50) (show all 226)
# Title Authors PMID Year
1
Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. 54 61
17959228 2008
2
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. 54 61
15448002 2004
3
Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. 54 61
11342771 2001
4
The outcome of childhood adrenocortical carcinoma in Egypt: A model from developing countries. 61
31971470 2020
5
A Rare Case of Insulinoma: A Case Report. 61
31915362 2020
6
Redox Status and Antioxidative Cofactor Metals Influence Clinical and Pathological Characteristics of Papillary Thyroid Carcinoma and Colloid Goiter. 61
31811573 2019
7
INCREASED SERUM CALCITONIN IN SPORADIC PRIMARY HYPERPARATHYROIDISM IS AN UNCOMMON OCCURRENCE. 61
31412223 2019
8
A novel case of myxoid variant of adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1. 61
31118348 2019
9
Pancreatic Polypeptide-Secreting Tumour of the Proximal Pancreas (PPoma)-Ultra Rare Pancreatic Tumour: Clinically Malign, Histologically Benign. 61
31450729 2019
10
Non-functional thyroid cystadenoma in three boxer dogs. 61
31277644 2019
11
Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific. 61
30862353 2019
12
Follicular thyroid carcinoma metastatic to skin: a small papule and a big diagnostic change. 61
30726467 2019
13
Sporadic Medullary Thyroid Carcinoma with Paraneoplastic Cushing Syndrome. 61
31885947 2019
14
Pediatric thyroid surgery: experience in 75 consecutive thyroidectomies. 61
30382398 2019
15
Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs. 61
30031098 2018
16
Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review. 61
29922966 2018
17
Gastrinoma of Cystic Duct: A Rare Association With Multiple Endocrine Neoplasia Type 1. 61
30344820 2018
18
Gastrinoma and Zollinger-Ellison syndrome in canids: a literature review and a case in a Mexican gray wolf. 61
29860931 2018
19
The epigenetic landscape of differentiated thyroid cancer. 61
28711609 2018
20
Ethnic specific differences in endocrine neoplasms: The role of susceptibility genes. 61
29246404 2018
21
Thyroid cancer phenotypes in relation to inflammation and autoimmunity. 61
29772561 2018
22
Unusual gastric subepithelial tumor: primary mixed acinar-endocrine neoplasm in an anemic woman. 61
29102730 2018
23
Educational Case: Endocrine Neoplasm: Medullary Thyroid Carcinoma. 61
29978018 2018
24
LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer. 61
29299168 2017
25
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. 61
28731042 2017
26
Cystic pancreatic neuroendocrine tumors (cPNETs): a systematic review and meta-analysis of case series. 61
29072081 2017
27
Multiple recurrences require long-term follow-up in patients diagnosed with spindle cell oncocytoma of the sella turcica. 61
28668473 2017
28
Low dose of Bisphenol A enhance the susceptibility of thyroid carcinoma stimulated by DHPN and iodine excess in F344 rats. 61
29050248 2017
29
Laparoscopic splenopancreatectomy for an endocrine tumor with cystic changes: a case report. 61
28265400 2017
30
Parathyroid carcinoma: an unusual presentation of a rare neoplasm. 61
29354025 2017
31
Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. 61
28469731 2017
32
Renal cell carcinoma metastasizing to pancreatic neuroendocrine neoplasm - the second case described in the world literature. 61
28547985 2017
33
Pancreatic Endocrine Neoplasm Concomitant with a Complicated Endocrine History: A Case Report and Literature Review. 61
30631835 2017
34
Solid-Pseudopapillary neoplasm of the pancreas: A clinicopathological review of 20 cases including rare examples. 61
28327291 2016
35
Using the Root of the Mesentery to Guide a Novel Operative Approach for Laparoscopic Insulinoma Resection. 61
27171819 2016
36
Resistance of papillary thyroid cancer stem cells to chemotherapy. 61
27347201 2016
37
B-Raf mutation and papillary thyroid carcinoma patients. 61
27073540 2016
38
Incidental Diagnosis of MEN1 Syndrome in a Pediatric Patient Presenting With Obstructive Jaundice and Abdominal Pain. 61
27144202 2016
39
Mouse models of thyroid cancer: A 2015 update. 61
26123589 2016
40
Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. 61
27834132 2016
41
Pituitary adenoma-neuronal choristoma is a pituitary adenoma with ganglionic differentiation. 61
26551086 2015
42
Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. 61
26022452 2015
43
Endovascular treatment of post-laparoscopic pancreatectomy splenic arteriovenous fistula with splenic vein aneurysm. 61
26167091 2015
44
P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters. 61
25835106 2015
45
Solid pseudopapillary neoplasm collides with a well-differentiated pancreatic endocrine neoplasm in an adult man: case report and review of histogenesis. 61
25596255 2015
46
WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old? 61
25266640 2014
47
Anaplastic thyroid carcinoma with diffuse thoracic skin metastasis: A case report. 61
24932230 2014
48
Cytologic features of solid pseudopapillary neoplasms of the pancreas: a single institutional experience based on evaluation of diagnostic utility of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). 61
25291866 2014
49
Recurrent ZFX mutations in human sporadic parathyroid adenomas. 61
25594030 2014
50
Nuclear medicine imaging of endocrine neoplasms. 61
24201551 2014

Variations for Endocrine Gland Cancer

Expression for Endocrine Gland Cancer

Search GEO for disease gene expression data for Endocrine Gland Cancer.

Pathways for Endocrine Gland Cancer

Pathways related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
2 10.71 MIR9-1 MIR221 MIR199A1

GO Terms for Endocrine Gland Cancer

Cellular components related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 SST MIR30A MIR221 MIR21 MIR199A1 MIR17

Biological processes related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 RET MIR34A MIR30A MIR21 MIR125A
2 negative regulation of cell proliferation GO:0008285 9.96 SST MIR9-1 MIR221 MIR214 MIR21
3 negative regulation of gene expression GO:0010629 9.88 MIR214 MIR21 MIR17 MIR125A
4 positive regulation of protein kinase B signaling GO:0051897 9.83 RET MIR221 MIR21 MIR199A1
5 negative regulation of cell migration GO:0030336 9.78 MIR9-1 MIR34A MIR214 MIR21
6 negative regulation of angiogenesis GO:0016525 9.71 MIR34A MIR214 MIR21 MIR125A
7 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.69 MIR30A MIR221 MIR214
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.67 MIR483 MIR221 MIR196A1
9 negative regulation of sprouting angiogenesis GO:1903671 9.63 MIR34A MIR221 MIR17
10 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
12 negative regulation of lamellipodium assembly GO:0010593 9.54 MIR214 MIR196A1
13 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.54 MIR34A MIR214 MIR21
14 positive regulation of connective tissue replacement GO:1905205 9.5 MIR34A MIR214 MIR199A1
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MIR221 MIR214 MIR21 MIR17
16 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.43 MIR221 MIR214
17 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR214 MIR199A1 MIR17
18 miRNA mediated inhibition of translation GO:0035278 9.43 MIR9-1 MIR483 MIR30A MIR221 MIR21 MIR17
19 gene silencing by miRNA GO:0035195 9.36 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214

Molecular functions related to Endocrine Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214

Sources for Endocrine Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....